305 related articles for article (PubMed ID: 38254784)
1. It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective.
Zaalberg A; Pottendorfer E; Zwart W; Bergman AM
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254784
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics in prostate cancer: clinical implications.
Conteduca V; Hess J; Yamada Y; Ku SY; Beltran H
Transl Androl Urol; 2021 Jul; 10(7):3104-3116. PubMed ID: 34430414
[TBL] [Abstract][Full Text] [Related]
3. Crosstalk between epigenetics and tumor promoting androgen signaling in prostate cancer.
Singh VK; Kainat KM; Sharma PK
Vitam Horm; 2023; 122():253-282. PubMed ID: 36863797
[TBL] [Abstract][Full Text] [Related]
4. Elucidation of the Genomic-Epigenomic Interaction Landscape of Aggressive Prostate Cancer.
Kumar Mamidi TK; Wu J; Hicks C
Biomed Res Int; 2021; 2021():6641429. PubMed ID: 33511206
[TBL] [Abstract][Full Text] [Related]
5. Molecular heterogeneity in prostate cancer and the role of targeted therapy.
Khan S; Baligar P; Tandon C; Nayyar J; Tandon S
Life Sci; 2024 Jan; 336():122270. PubMed ID: 37979833
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets.
Yang J; Xu J; Wang W; Zhang B; Yu X; Shi S
Signal Transduct Target Ther; 2023 May; 8(1):210. PubMed ID: 37217462
[TBL] [Abstract][Full Text] [Related]
7. New approaches to targeting epigenetic regulation in prostate cancer.
Thompson D; Choo N; Bolton DM; Lawrentschuk N; Risbridger GP; Lawrence MG; Taylor RA
Curr Opin Urol; 2022 Sep; 32(5):472-480. PubMed ID: 35869742
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic mechanism of therapeutic resistance and potential of epigenetic therapeutics in chemorefractory prostate cancer.
Roy P; Singh KP
Int Rev Cell Mol Biol; 2023; 380():173-210. PubMed ID: 37657858
[TBL] [Abstract][Full Text] [Related]
9. Advances of Epigenetic Biomarkers and Epigenome Editing for Early Diagnosis in Breast Cancer.
Sarvari P; Sarvari P; Ramírez-Díaz I; Mahjoubi F; Rubio K
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076918
[TBL] [Abstract][Full Text] [Related]
10. Microbiota and the landscape of the prostate tumor microenvironment.
Gupta KR; Kyprianou N
Am J Clin Exp Urol; 2023; 11(5):352-360. PubMed ID: 37941651
[TBL] [Abstract][Full Text] [Related]
11. New insights and options into the mechanisms and effects of combined targeted therapy and immunotherapy in prostate cancer.
Lin M; Sun X; Lv L
Mol Ther Oncolytics; 2023 Jun; 29():91-106. PubMed ID: 37215386
[TBL] [Abstract][Full Text] [Related]
12. The cancer epigenome: Non-cell autonomous player in tumor immunity.
Kato S; Maeda Y; Sugiyama D; Watanabe K; Nishikawa H; Hinohara K
Cancer Sci; 2023 Mar; 114(3):730-740. PubMed ID: 36468774
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic Modifications in Tumor-Associated Macrophages: A New Perspective for an Old Foe.
Niu Y; Chen J; Qiao Y
Front Immunol; 2022; 13():836223. PubMed ID: 35140725
[TBL] [Abstract][Full Text] [Related]
14. Aberrant DNA methylation and prostate cancer.
Majumdar S; Buckles E; Estrada J; Koochekpour S
Curr Genomics; 2011 Nov; 12(7):486-505. PubMed ID: 22547956
[TBL] [Abstract][Full Text] [Related]
15. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.
Harris AE; Metzler VM; Lothion-Roy J; Varun D; Woodcock CL; Haigh DB; Endeley C; Haque M; Toss MS; Alsaleem M; Persson JL; Gudas LJ; Rakha E; Robinson BD; Khani F; Martin LM; Moyer JE; Brownlie J; Madhusudan S; Allegrucci C; James VH; Rutland CS; Fray RG; Ntekim A; de Brot S; Mongan NP; Jeyapalan JN
Front Endocrinol (Lausanne); 2022; 13():1006101. PubMed ID: 36263323
[TBL] [Abstract][Full Text] [Related]
16. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
17. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.
Msaouel P; Nandikolla G; Pneumaticos SG; Koutsilieris M
Expert Opin Investig Drugs; 2013 Nov; 22(11):1385-400. PubMed ID: 24024652
[TBL] [Abstract][Full Text] [Related]
18. Tumor microenvironment pH-responsive pentagonal gold prism-based nanoplatform for multimodal imaging and combined therapy of castration-resistant prostate cancer.
Tan H; Liu Y; Hou N; Cui S; Liu B; Fan S; Yu G; Han C; Zheng D; Li W; Liu Y; Xu B; Wang Z; Cui D
Acta Biomater; 2022 Mar; 141():408-417. PubMed ID: 35032718
[TBL] [Abstract][Full Text] [Related]
19. Exploiting Epigenetic Alterations in Prostate Cancer.
Baumgart SJ; Haendler B
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28486411
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic modifications in prostate cancer.
Sugiura M; Sato H; Kanesaka M; Imamura Y; Sakamoto S; Ichikawa T; Kaneda A
Int J Urol; 2021 Feb; 28(2):140-149. PubMed ID: 33111429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
